Christophe J, Waelbroeck M, Chatelain P, Robberecht P
Peptides. 1984 Mar-Apr;5(2):341-53. doi: 10.1016/0196-9781(84)90232-8.
We have assessed the presence of VIP/PHI/secretin receptors in heart by: (1) testing the ability of the corresponding peptides to activate adenylate cyclase in cardiac membranes from rat, dog, Cynomolgus monkey and man, and (2) examining the ability of the same peptides to exert inotropic and chronotropic effects on heart preparations from rat and Cynomolgus monkey in vitro. Based on their affinity for natural peptides and synthetic analogs, two types of VIP/PHI/secretin receptors were characterized: the relatively nonspecific "secretin/VIP receptor" of rat heart (that is "secretin-preferring" only in that secretin was more efficient than VIP in stimulating adenylate cyclase), and the "VIP/PHI-preferring" receptor of man, monkey and dog heart. Four physiopathological situations affecting secretin/VIP receptors in rat heart were explored: In male rats from the Okamoto strain and the Lyon strain, two strains presenting spontaneous hypertension, heart membranes exhibited a markedly decreased response of adenylate cyclase to secretin/VIP, with lesser alterations in the responses to isoproterenol and glucagon. This impairment developed in parallel with the occurrence of hypertension and was reproduced in normotensive rats submitted to chronic isoproterenol treatment (but not in Goldblatt hypertensive rats). These findings are consistent with a hyperactivity of norepinephrine pathways in spontaneously hypertensive rats, leading to a reduced number of cardiac post-junctional secretin/VIP receptors bound to adenylate cyclase. Heart membranes from genetically obese (fa/fa) Zucker rats also exhibited severely decreased responses to secretin/VIP with lesser alterations in the responses to glucagon and isoproterenol. These anomalies were specific for the heart, and developed in concomitance with obesity. The first anomaly could not be corrected by severe food restriction. Secretin stimulation of heart adenylate cyclase was also selectively altered in streptozotocin-diabetic rats. Thus, two types of diabetic cardiomyopathy were characterized by a severe local alteration of secretin/VIP receptors coupled to adenylate cyclase. Hypothyroidism, provoked in rat by thyroidectomy or propylthiouracil treatment, again induced a marked decrease in secretin-stimulated cardiac adenylate cyclase activity. In rat papillary muscle electrically stimulated in vitro, secretin exerted a positive inotropic effect. This effect was reduced in obese (fa/fa) Zucker rats. In rat right atrium, secretin also exerted a positive chronotropic effects.(ABSTRACT TRUNCATED AT 400 WORDS)
我们通过以下方式评估了心脏中血管活性肠肽(VIP)/胰高血糖素样肽(PHI)/促胰液素受体的存在情况:(1)检测相应肽段激活大鼠、犬、食蟹猴和人类心脏膜中腺苷酸环化酶的能力;(2)检测相同肽段对大鼠和食蟹猴离体心脏标本产生变力性和变时性效应的能力。基于它们对天然肽段和合成类似物的亲和力,鉴定出两种类型的VIP/PHI/促胰液素受体:大鼠心脏中相对非特异性的“促胰液素/VIP受体”(即仅在刺激腺苷酸环化酶方面促胰液素比VIP更有效时才“更倾向于促胰液素”),以及人类、猴和犬心脏中的“更倾向于VIP/PHI”受体。探讨了影响大鼠心脏促胰液素/VIP受体的四种生理病理情况:在冈本品系和里昂品系的雄性大鼠中,这两个品系表现出自发性高血压,心脏膜中腺苷酸环化酶对促胰液素/VIP的反应明显降低,对异丙肾上腺素和胰高血糖素的反应变化较小。这种损害与高血压的发生同时出现,并且在接受慢性异丙肾上腺素治疗的正常血压大鼠中也会出现(但在戈德布拉特高血压大鼠中不会出现)。这些发现与自发性高血压大鼠中去甲肾上腺素途径的过度活跃一致,导致与腺苷酸环化酶结合的心脏节后促胰液素/VIP受体数量减少。遗传性肥胖(fa/fa) Zucker大鼠的心脏膜对促胰液素/VIP的反应也严重降低,对胰高血糖素和异丙肾上腺素的反应变化较小。这些异常是心脏特有的,并且与肥胖同时出现。第一种异常不能通过严格的食物限制来纠正。链脲佐菌素诱导的糖尿病大鼠中,促胰液素对心脏腺苷酸环化酶的刺激也有选择性改变。因此,两种类型的糖尿病性心肌病的特征是与腺苷酸环化酶偶联的促胰液素/VIP受体存在严重的局部改变。通过甲状腺切除术或丙硫氧嘧啶治疗在大鼠中诱发的甲状腺功能减退,再次导致促胰液素刺激的心脏腺苷酸环化酶活性显著降低。在体外电刺激的大鼠乳头肌中,促胰液素发挥正性变力作用。在肥胖(fa/fa) Zucker大鼠中这种作用减弱。在大鼠右心房中,促胰液素也发挥正性变时作用。(摘要截取自400字)